Mineralys Therapeutics, Inc.
MLYS
Rank in Stocks
#7275
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company,... Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Share Price
$15.81
Last synced: 2026-11-09
Market Cap
$1.40B
Change (1 day)
3.13%
Change (1 year)
-66.60%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Mineralys Therapeutics, Inc. (MLYS)
Category
Healthcare
EPS for Mineralys Therapeutics, Inc. (MLYS)
EPS as of September 2026 TTM: $-4.36
According to Mineralys Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-4.36. At the end of 2025 the company had an EPS of $-2.29, an increase over its 2024 EPS of $-3.66.
EPS history for Mineralys Therapeutics, Inc. from 2020 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-4.36 | 90.39% |
| 2025 | $-2.29 | -37.43% |
| 2024 | $-3.66 | 83.92% |
| 2023 | $-1.99 | -65.51% |
| 2022 | $-5.77 | 48.33% |
| 2021 | $-3.89 | 425.68% |
| 2020 | $-0.74 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -459.17% |
US
|
|
| $-7.07 | 62.16% |
US
|
|
| $-5.29 | 21.33% |
AU
|
|
| $12.88 | -395.42% |
BE
|
|
| $21.56 | -594.50% |
NL
|
Questions about Mineralys Therapeutics, Inc.'s earnings per share (EPS)
What is Mineralys Therapeutics, Inc.'s earnings per share (EPS)?
Mineralys Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-4.36, as of Sep 2026.
What was Mineralys Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Mineralys Therapeutics, Inc.'s earnings per share (EPS) was $-2.29, compared with $-3.66 in 2024.
How has Mineralys Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Mineralys Therapeutics, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.74) and lowest in 2022 ($-5.77).
How does Mineralys Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Mineralys Therapeutics, Inc.'s earnings per share (EPS) ($-4.36) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.